Price
Frequently asked questions
What is Calidi's market capitalization?
What is the Earnings Per Share (EPS) for Calidi?
What are the analyst ratings and target price for Calidi's stock?
What is the EBITDA for Calidi?
What is the free cash flow of Calidi?
How many employees does Calidi have, and what sector and industry does it belong to?
What is the free float of Calidi's shares?
Financials
Market Cap
$37.66MEPS (TTM)
-$5.611Free Float
15.40MEBITDA (TTM)
-$27.17MFree Cashflow (TTM)
-$19.54MPricing
Analyst Ratings
The price target is $20.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
41
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker